Released Products with Masimo SET®:
(Move mouse over instrument names to see pictures.)
Atom Medical Corporation
3-18-15 Hongo Bunkyo-Ku
Tokyo, Japan 113-0033
Phone: +81 3 3815 2311
Fax: +81 3 3812 3144
Atom Medical Adopts Masimo Rainbow SET Technology
Irvine, California – April 16, 2008 – Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion pulse oximetry, today announced an agreement with Atom Medical Corporation, a leading global manufacturer of neonatal products and technologies, to integrate Masimo Rainbow SET Pulse CO-Oximetry into its current and future product solutions.
"Since standardizing on Masimo technology more than 10 years ago, our neonatal monitoring solutions and customers have greatly benefited from the superior performance of Masimo SET pulse oximetry," said Kazuo Matsubara, President of Atom Medical. "Now, with the groundbreaking capabilities of Masimo Rainbow SET and its ability to provide vital measurements that previously required invasive lab procedures, we are confident that the clinical community which we serve will experience even greater clinical and financial benefits from our solutions."
Masimo Rainbow SET is the first and only technology platform capable of noninvasively and continuously measuring total hemoglobin (SpHb™) and oxygen content (SpOC™)—both measurements pending FDA and other regulatory clearances—as well as carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and pleth variability index (PVI®), in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR).
Masimo Rainbow SET has the potential to help clinicians save lives through more rapid diagnosis of potentially life-threatening conditions, allowing faster treatment decisions and improved patient outcomes. The latest Masimo Rainbow SET measurement, SpHb, may enable medical personnel in both hospital and outpatient settings to quickly identify anemia or blood loss without having to draw blood or wait for lab results.
In neonatal settings, the ability to continuously and noninvasively measure a patient's methemoglobin levels is especially important due to the risks associated with the use of inhaled nitric oxide (iNO) therapy to treat hypoxic respiratory failure in newborns, which has been shown to induce methemoglobinemia. According to the American Academy of Pediatrics, "infants who receive iNO therapy should be monitored according to institutionally derived protocols designed to avoid the potential toxic effects associated with iNO administration. These effects include methemoglobinemia (secondary to excess nitric oxide concentrations), direct pulmonary injury (attributable to excess levels of nitrogen dioxide), and ambient air contamination."
Masimo Chairman and CEO, Joe E. Kiani, said, "Atom is a long-time Masimo partner dedicated to developing innovative solutions for the challenging neonatal clinical setting. The addition of Masimo Rainbow SET affirms their position as a leading global provider of advanced neonatal product solutions, leveraging breakthrough technologies to improve the quality of care for the tiniest of patients. We commend Atom for their commitment to patient care and product innovation."
About Atom Medical Corporation
Atom Medical has an active and strong sales network is made up of over 50 overseas distributors who market, sell, and service Atom's name brand perinatal products to hospitals and clinicians in over 90 countries. In addition, long term relationships with over ten international medical manufacturers ensure that local clinical needs can be met with the latest imported medical products. Atom Medical will continue its commitment to providing the finest in medical products and care to its worldwide customers.
PLCO-000349/PLMM-10060B-0816